Adamis Pharma Stock Jumps After Naloxone Injection Under FDA Review For Opioid Overdose
- The FDA has accepted for review Adamis Pharmaceuticals Corporation's (NASDAQ: ADMP) marketing application seeking approval for Zimhi, a naloxone injection for opioid overdose.
- The agency's target action date is November 12.
- The company resubmitted the application in May after it received a complete response letter in November 2020.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: ADMP shares are up 11.9% at $1.13 during the premarket session on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs OpioidsBiotech News Penny Stocks Health Care FDA General